Guildford, UK, 9 January 2007: ReNeuron Group plc (LSE: RENE) today provides an update regarding its recently filed Investigational New Drug (IND) application to commence a Phase I clinical study for its ReN001 stem cell therapy for stroke. The US Food and Drug Administration (FDA) has orally confirmed that it has placed the proposed clinical study on hold. A telephone conference call with the FDA to discuss the application is expected to take place later this week, following which the Company will make a further announcement.
Michael Hunt, Chief Executive Officer of ReNeuron, said:
We are encouraged to be able to engage in an immediate dialogue with the FDA regarding our IND application, now that the initial review process has taken place. Given the ground-breaking nature of our ReN001 therapy and the lack of comparable approaches addressing stroke, it is not surprising that the FDA might wish to raise questions or make comments at this point in the approval process. We look forward to a constructive dialogue with the FDA and, in the meantime, we continue with our ongoing preparations for the initial ReN001 clinical study.”
Notes to editors
ReNeuron is a leading, UK-based adult stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.
ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national
patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.
ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. This represents the world’s first such filing concerning a neural stem cell treatment for a major neurological disorder. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.
ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington’s disease, a genetic and fatal neurodegenerative disorder that affects around 1 in 10,000 people. This programme is in pre-clinical development.
In addition to its stroke and Huntington’s disease programmes, ReNeuron is developing stem cell therapies for Parkinson’s disease, Type 1 diabetes and diseases of the retina.
ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas � its ReNcellTM range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron’s ReNcellTM CX and ReNcellTM VM neural cell lines are marketed worldwide under license by Millipore Corporation.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.
Further information on ReNeuron and its products can be found at www.reneuron.com.
Data sources: UK Stroke Association, American Stroke Association.
Michael Hunt, CEO
Tel: 44 (0)1483 302 560
Tel: 44 (0)20 7831 3113
The terms �ReNeuron’, �the Company’ or �the Group’ used in this statement refer to ReNeuron Group plc and/or its subsidiary undertakings, depending on the context.